2013 年 71 巻 5 号 p. 433-442
In general, biologically active drug lead molecules are structurally complex, bearing multiple functional groups and chiral sp3 carbons. Our aim in developing new catalysis is to promote a concise, robust, and clean drug lead synthesis. To do so requires catalysis allowing for the design of concepually new retrosynthesis independent of functional groups. Here we summarize our first step toward such a goal. First, we describe a Cu(I)-catalyzed enantioselective condensation of ketones and hemiaminals that can produce versatile chiral building blocks for alkaloid synthesis. The hard anion-conjugated soft metal (HASM) catalysis concept is the basis for the reactivity. Second, two Cu-catalyzed cross-dehydrogenative coupling (CDC) reactions are discussed. The radical-conjugated redox catalysis (RCRC) concept leads to the development of a very early example of catalytic asymmetric aerobic CDC. Third, the Rh-catalyzed aldehyde cross aldol reaction and the Co-catalyzed C-4 selective alkylation of pyridines, both of which are mediated by means of hydride transfer, are described. Unique reactivity in the latter two topics is partly due to the redox activity of the transition metal catalysts.